Modular megaprosthesis for distal femoral tumors

Ilyas, Imran; Kurar, A; Pg, Moreau; Da, Younge

doi:10.1007/s002640100290

Cited by 79 publications

(75 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The functional outcome can hardly be influenced positively even by using a connecting tube in proximal and total femur replacement. McGoveran et al [14] reported an MSTS score of 58.3%, and Ilyas et al [10] of 63.3% following proximal femur replacement nicely matching our results with 67%.…”

Section: Discussionsupporting

confidence: 81%

Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours—a comparative analysis using the MSTS score, the TESS and the RNL index

Tunn

Pomraenke

Goerling

et al. 2007

International Orthopaedics (SICO

View full text Add to dashboard Cite

Limb-saving therapy for primary bone tumours is the treatment of choice. We aimed at analysing the quality of life of this group of patients by combining three different tools. Eighty-seven patients (46 females, 41 males) with a primary bone tumour of the extremity who had undergone endoprosthetic reconstruction between 1982 and 2000 were included in this retrospective study. The median age at the time of evaluation was 30 (12-73) years. The Toronto Extremity Salvage Score (TESS) and the Reintegration to Normal Living index (RNL) were recorded an average of 5.8 years after reconstruction and the Musculoskeletal Tumour Society Score (MSTS) after an average of 6.5 years. The mean MSTS score was 77% (13-93%). The mean TESS was 82% (22-99%), and the mean RNL index was 87% (32-98%). The subjective satisfaction and acceptance of physical impairment were significantly higher than the objective score (p<0.001). The TESS was 88% in patients aged 12-25 years, 81% in those aged 26-40 years and 57% in those aged 41-73 years. Parallel recording of the MSTS score, TESS and RNL index provides a better measure reflecting the complex situation of the patients by combining objective and subjective parameters.

show abstract

Section: Discussionsupporting

confidence: 81%

Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours—a comparative analysis using the MSTS score, the TESS and the RNL index

Tunn

Pomraenke

Goerling

et al. 2007

International Orthopaedics (SICO

View full text Add to dashboard Cite

show abstract

“…These results compare well with those observed by Mittermayer et al, who observed a 5-year prosthetic survival of 79% and a 10-year survival of 71% [16]. Roberts et al reported a 5-year prosthetic survival of 74.9% [17], and Ilyas et al observed a 10-year prosthetic survival of 65% in a series of 48 patients [10].…”

Section: Discussionsupporting

confidence: 80%

Distal femoral tumours treated by resection and custom mega-prosthetic replacement

Natarajan

Sivaseelam

Ayyappan

et al. 2005

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

We have analysed the results of 246 cases of distal femoral tumours treated by resection and prosthetic replacement between 1988 and 2002. Patient ages ranged from 6-67 years averaging 24 years; 133 were males. The most common tumour was osteosarcoma (67% of patients). The follow-up ranged from 2 to 14 years. Stage II tumours were seen in 72% of patients. The technique of sleeve resection of the quadriceps musculature was followed to achieve local clearance of the tumour. The prosthesis used was a rotating hinge custom mega-prosthesis manufactured locally. The functional result achieved was excellent or good in 87%; 86% of the patients had no evidence of disease, and 13% had died. The 10-year patient survival was 76.9%. Periprosthetic fracture and infection were the most common complications.Résumé Nous avons analysé les résultats de 246 cas de tumeurs fémorales distales traitées par résection et remplacement prothétique entre 1988 et 2002. L'âges des malades s'étendait de 6 à 67 ans avec une moyenne de 24 ans. Cent trente trois étaient des hommes. La tumeur la plus fréquente était l'ostéosarcome (67% des malades). Le suivi était de 2 à 14 années. Des tumeurs de stade II étaient présentes chez 72% des malades. La technique de résection a été conduite pour faire une ablation complète de la tumeur. La prothèse qui a été utilisée était une méga prothèse à charnière rotatoire fabriqué localement. Le résultat fonctionnel obtenu était excellent ou bon dans 87%. Quatre-vingt-six pourcent des malades n'avait pas d'évidence de maladie et 13% étaient morts. La survie à dix ans était de 76,9%. Les fractures périprothétiques et l'infection étaient les complications les plus fréquentes.

show abstract

“…Because malignant bone tumors are rare, reports about survivorship and complications of tumor endoprostheses generally are limited to small cohorts with relatively short followup [6,7,10,14,15] and commonly these investigations apply Kaplan-Meier estimations and Cox regression models to describe endoprosthetic survival. These analyses deal principally with one event as an endpoint, for example revision surgery, independent of its cause [20].…”

Section: Introductionmentioning

confidence: 99%

Does Competing Risk Analysis Give Useful Information About Endoprosthetic Survival in Extremity Osteosarcoma?

Schuh

Kaider

Windhager

et al. 2015

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Conventional survival analysis for endoprosthetic complications does not consider competing events adequately. Patients who die of their disease are no longer at risk for complications; therefore, death as a competing event may alter survivorship estimates in the orthopaedic-oncological setting. Questions/purposes This investigation aimed to compare (1) endoprosthetic survivorship after osteosarcoma by Kaplan-Meier analysis; and (2) by a competing risk model. Methods Between 1981 and 2009, we performed 247 modular endoprostheses for patients with extremity osteosarcoma; 73 patients had a followup of less than 2 years but all patients were included in statistical analysis. No patients were lost to followup for reasons other than death. Revision-free endoprosthetic survival until soft tissue failure (Type 1), aseptic loosening (Type 2), structural failure (Type 3), infection (Type 4), and local tumor progression (Type 5) was estimated according to a KaplanMeier analysis and a competing risk model. Sixty-four patients died throughout followup; the 5-and 10-year overall survival and metastasis-free survival were 72% and 70% and 70% and 69%, respectively. One hundred twentytwo patients (49%) had complications.

show abstract

Modular megaprosthesis for distal femoral tumors

Cited by 79 publications

References 16 publications

Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours—a comparative analysis using the MSTS score, the TESS and the RNL index

Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours—a comparative analysis using the MSTS score, the TESS and the RNL index

Distal femoral tumours treated by resection and custom mega-prosthetic replacement

Does Competing Risk Analysis Give Useful Information About Endoprosthetic Survival in Extremity Osteosarcoma?

Contact Info

Product

Resources

About